Treatment Persistence and Healthcare Costs Among Patients with Rheumatoid Arthritis After a Change in Targeted Therapy

BACKGROUND: Targeted disease-modifying antirheumatic drug (DMARD) options for rheumatoid arthritis (RA) include tumor necrosis factor (TNF) inhibitors (adalimumab, certolizumab, etanercept, golimumab, infliximab) or alternative mechanisms of action (MOAs), such as a T-cell co-stimulation modulator (...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Am Health Drug Benefits
Main Authors: Bonafede, Machaon M. K., McMorrow, Donna, Proudfoot, Clare, Shinde, Shraddha, Kuznik, Andreas, Chen, Chieh-I
Formato: Artigo
Idioma:Inglês
Publicado em: Engage Healthcare Communications, LLC 2018
Assuntos:
Business
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6207310/
https://ncbi.nlm.nih.gov/pubmed/30464787
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados